Venmax Drugs & Pharmaceuticals Ltd.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. carries a market capitalization of 214.17M, placing it among publicly traded companies globally. Its enterprise value stands at 89.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. has 11.58M shares outstanding.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 60.95. The price-to-sales ratio is 1.84, and the price-to-book ratio stands at 1.43.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 58.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 60.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 89.74M versus a market cap of 214.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. maintains a current ratio of 9.23, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.40, indicating moderate leverage, while an interest coverage ratio of 255.50 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. posted a return on equity (ROE) of 2.89, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.37 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.86, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.47 indicates how many times Venmax Drugs & Pharmaceuticals Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. recorded 288,700.00 in income tax expense. That works out to an effective tax rate of 9.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.09M, leaving 2.80M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Venmax Drugs & Pharmaceuticals Ltd.'s stock has declined approximately 44.58% over the past 52 weeks. The 50-day moving average sits at 15.35, while the 200-day moving average is 21.29.

Over the twelve months ended June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. generated 92.94M in revenue and converted that into 2.80M in net income, yielding earnings per share of 0.30. EBITDA reached 1.53M, while operating income came in at 1.49M.

As of June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. holds 126.54M in cash and equivalents against 2.11M in total debt, resulting in a net debt position of -6.11M. Total book value stands at 150.08M, with working capital of 149.68M providing operational flexibility.

Venmax Drugs & Pharmaceuticals Ltd. produced -121.44M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -58,000.00 in capital expenditures, free cash flow totaled -121.50M - equivalent to -13.15 per share.

Over the twelve months ended June 30, 2026, Venmax Drugs & Pharmaceuticals Ltd. posted a gross margin of 9.20, reflecting its pricing power and cost economics. The operating margin of 1.60 and net profit margin of 3.02 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -71.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -48.80, meaning Venmax Drugs & Pharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Venmax Drugs & Pharmaceuticals Ltd.'s most recent stock split took place on January 29, 2009 with a 2:1 split ratio.